Featured in this issue

EDITORIAL
Makela M: Exchanging views on HTA

ASSESSMENTS
Galvao F et al.: Economic evaluation of poison centers: A systematic review
Lim M et al.: The case of emergency department waiting times
Bastani P and Kiadaliri AA: Cost-utility of adjuvant therapies for breast cancer in Iran
Youn JH et al.: Bayesian meta-analysis on medical devices

METHODS
John M and Norheim O: Methods to consider equity in CEA
Golder S and Loke YK: Information sources for adverse effects data
Morrison A et al.: English-language restriction in systematic reviews
Maklin S et al.: QALYs in the evaluation of screening programs
Tan SS et al.: Dutch Manual for costing
Drummond M et al.: Can we reliably benchmark HTA organizations?

COMMENTS
Sampietro-Colom L: Consider context and stakeholders
Henshall C: Describe decision making systems, assess HTA reports
Goodman C: Toward international good practices in HTA

POLICIES
Mad P et al.: Pre-coverage assessment of new hospital interventions
Pichon-Riviere A et al.: HTA transferability in Latin America
Bending M et al.: Drug reimbursement agencies in France and Scotland

LETTERS
Dengler K and Bittner U: What do we mean by talking about “value(s)”?
Hofmann B et al.: To evaluate versus to know the value of everything
CONTENTS

EDITORIAL

85 Exchanging views on HTA
Marjukka Mäkelä

ASSESSMENTS

86 Economic evaluation of poison centers: A systematic review
Tais F. Galvao, Everton N. Silva, Marcus T. Silva, Alvin C. Bronstein, and Mauricio G. Pereira

93 Mathematical modeling: The case of emergency department waiting times
Morgan E. Lim, Tim Nye, James M. Bowen, Jerry Hurley, Ron Goeree, and Jean-Eric Tarride

110 Cost-utility analysis of adjuvant therapies for breast cancer in Iran
Peivand Bastani and Aliasghar Ahmad Kiadaliri

115 Bayesian meta-analysis on medical devices: Application to implantable cardioverter defibrillators
Ji-Hee Youn, Joanne Lord, Karla Hemming, Alan Girling, and Martin Buxton

METHODS

125 Can cost-effectiveness analysis integrate concerns for equity? Systematic review
Mira Johri and Ole Frithjof Norheim

133 The contribution of different information sources for adverse effects data
Su Golder and Yoon K. Loke

138 The effect of English-language restriction on systematic review-based meta-analyses: A systematic review of empirical studies
Andra Morrison, Julie Polisena, Don Husereau, Kristen Mouton, Michelle Clark, Michelle Fiander, Monika Mierzwinski-Urban, Tammy Clifford, Brian Hutton, and Danielle Rabb

145 Quality-adjusted life-years for the estimation of effectiveness of screening programs: A systematic literature review
Suvi Mäklin, Pirjo Räsänen, Riikka Laitinen, Niina Kovanen, Ilona Autti-Rämö, Harri Sintonen, and Risto P. Roine

152 Update of the Dutch Manual for costing in economic evaluations
Siok Swan Tan, Clazien A. M. Bouwmans, Frans F. H. Rutten, and Leona Hakkaart-van Roijen

159 Can we reliably benchmark health technology assessment organizations?
Michael Drummond, Peter Neumann, Bengt Jönsson, Bryan Luce, J. Sanford Schwartz, Uwe Siebert, and Sean D. Sullivan, for the International Group for HTA Advancement

COMMENTS

166 Consider context and stakeholders
Laura Sampietro-Colom

168 Describe decision-making systems, assess health technology assessment reports
Chris Henshall

169 Toward international good practices in health technology assessment
Clifford Goodman

https://doi.org/10.1017/S0266462312000207 Published online by Cambridge University Press
POLICIES

171 Pre-coverage assessments of new hospital interventions on Austria: Methodology and 3 years of experience
Philipp Mad, Sabine Geiger-Gritsch, Gerda Hinterreiter, Stefan Mathis-Edenhofer, and Claudia Wild

180 Transferability of health technology assessment reports in Latin America: An exploratory survey of researchers and decision makers
Andres Pichon-Riviere, Federico Augustovski, Sebastián García Martí, Sean D. Sullivan, and Michael Drummond

187 A comparison of pharmaceutical reimbursement agencies’ processes and methods in France and Scotland
Matthew Bending, John Hutton, and Clare McGrath

LETTERS

195 What do we mean by talking about “value(s)”? A Reply to Saarni et al.
Kathrin Dengler and Uta Bittner

196 To evaluate versus to know the value of everything
Bjørn Hofmann, Samuli I. Saarni, Annette Braunack-Mayer, and Gert Jan van der Wilt